Abstract-We address the problem of collecting and analyzing vast amount of information in medicine and biology, in the light of the revolutionary technological evolution during the last decades. Currently, the methods of achieving information challenge our capacity to sort and process that data. However, we use the methods of machine learning to sort and analyze this information. In this comprehensive review we describe an experiment of analyzing DNA microarrays using a Genetic Algorithm for feature selection. We study how we can establish a causal relationship between a pattern of genic expression and the evolution of pancreatic cancer using a Genetic Algorithm.
I. INTRODUCTION
In last decades, information technology generated a revolution in medicine, in all areas, from diagnosis techniques to high level surgery procedures. In this context, we witness a spectacular revolution in genetics. The complexity of the research process became so overwhelming, that it is almost impossible these days to develop a breakthrough research in medicine without the collaboration of scientists from completely different fields. We expect that future development will provide us with new diagnostic methods and treatments capable to heal some of the worst prognosticated diseases nowadays.
The Pancreatic Cancer is still a big challenge for the medicine at the moment. The lack of an efficient screening and the unspecific simptomatology make early diagnosis almost impossible in most of the cases. Consequently to late diagnosis, the treatment is inefficient, and we witness a very high rate of mortality.
The DNA microarrays ( Fig. 1 ) are glass or plastic chips which immobilize thousands to hundred thousands samples of DNA fragments, cDNA or oligonucleotides, depending of chip construction technology. The microarray technology allows the comparison of samples collected from normal and tumor biological probes, in terms of differentially expressed genes. In this manner, we can establish a causal relationship between a pattern of genic expression and the evolution of a malignant process; to find the markers of that specific process. The microarray technology sets the basis for very efficient screening and diagnosing cancer in an early stage of development. It could also expand into a starting point for developing new treatments for various types of cancer.
Our experiment represents a specific step in a more complex research project concerning the pancreatic cancer. The project "Gene Expression Profile and Biomarkers Study Correlated with Clinicopathological Parameters in Pancreatic Cancer" (GENOPACT) is a Romanian National Grant, CEEX 56/2005, developed by the Department of Surgery within the Fundeni Clinical Institute in collaboration with several academic and research institutes. The aim of the GENOPACT project is to discover a group of markers for the pancreas cancer, which will increase the efficiency of diagnosing the disease in early stages. Finding an optimal subset of differentially expressed genes is a very important task in achieving this goal.
II. PROBLEM STATEMENT
The problem we are addressing here is how we process the information provided by microarrays in order to achieve knowledge. Nowadays, the methods of machine learning and statistics are key factors of the research. The number of probes immobilized on a single array grows every year, consequently, the complexity of the analysis increases.
We are interested in finding a group of differentially expressed genes that characterize the process in pancreatic cancer. Using Affymetrix HG-U133 Plus 2 arrays, we will compare samples collected from normal and tumor cells, derived from patients diagnosed with pancreatic cancer.
The main drawbacks of microarray technology are the background noise and the insufficient sensitivity. It is very difficult to distinguish between the genes that are causally involved in the process of interest, and the genes that are differentially expressed as consequences of another process.
We will use Machine learning techniques to overcome these problems. Our goal is to select, from all the differentially expressed probes, a subset of probes that we A Genetic Algorithm Approach to DNA Microarrays Analysis of Pancreatic Cancer Nicolae Teodor MELITA 1 , Stefan HOLBAN can use to discriminate very well between the normal and tumor samples. However, the machine learning techniques give an image of the problem, but further biological validation is needed to draw solid scientific conclusions. We will use a Genetic Algorithm (GA) to select a subset of differentially expressed genes from the microarray data, we will study how efficient this subset proves to be in discriminating between the normal and tumor samples, and we will briefly inspect the biological significance of our experiment.
III. SURVEY OF THE LITERATURE
Because we are dealing with a relatively new interdisciplinary field, the literature is devised between all the research fields involved. We are interested in a better understanding of our dataset, so we want to know about the methods of biotechnology for creating microarrays and providing data to be analyzed (Causton, Quackenbush & Brazma, 2003 [1] ). Other approaches focus on the bioinformatics' point of view on methods of collecting and analyzing data (Dov Stekel, 2003 [2] ). The books that focus on the specific machine learning methods help in developing an image of how the algorithms work, their strong and weak points (Ressom, A very helpful set of documents are focused on using the specific software tools that we need in microarray analysis with emphasis on specific features (Venables & Ripley, 2000 [6] ; D. G. Stork and E. Yom-Tov, 2004 [7] ; Robert Gentleman, Vince Carey, Wolfgang Huber, Rafael A. Irizarry, Sandrine Dudoit [8] , Sam Roberts [9] ). These books are designed to introduce the researchers in using these software packages fast and effective.
Currently, there are several software packages that offer the fitted tools for our analysis. The experiments presented in this review were performed in R (version 2.6.2), utilizing the Bioconductor Project. The R software and supplementary packages are freely downloadable on the official website: http://cran.r-project.org/. The Bioconductor software, all the additional packages and the accompanying documentation are freely available for download on the Project's website: http://www.bioconductor.org/.
IV. METHOD
Our experiment is a part of the project Genopact, CEEX 56/2005, developed by a multidisciplinary team, and supported by a group of healthcare providers, academic and research institutes. In this point of the research, we focus on selecting a subset of the probes that are optimal for discriminating between the normal and pancreatic cancer samples. Our analysis aims to restrict the group of genes assumed to have a causal relationship with the pancreatic cancer evolution.
The GENOPACT dataset consists of 39 pancreatic cancer-normal sample pairs collected from patients diagnosed and monitored at the Center of General Surgery and Liver Transplantation from Fundeni Clinical Institute.
The measurements were accomplished using Affymetrix HG-U133 Plus 2 arrays, resulting 78 microarray expression data.
First, we preprocessed the data using 5 algorithms (GCRMA, RMA, PLIER, MAS5, and LIWONG). The GCRMA granted the best results, so we developed our experiment based on this dataset. We assessed the quality of our data benefiting from the affy, affyQCReport, affycoretools, and simpleaffy R packages. The samples found to be problematic were removed. We continued the analysis with a dataset consisting of 70 samples.
We utilized the genefilter R package to apply a nonspecific filter on the dataset, removing the probes with IQR across the samples on the log base 2 < 0.5. Furthermore, the data was filtered using the moderated t-statistics computed with the limma package in R. The p-value=8e-09 was found to be the cut-off where the Affymetrix controls were not differentially expressed anymore. The dataset was filtered for probes with log fold change > 2.0 which were differentially expressed at p-value<8e-09. The result was a new dataset with 365 features.
Finally, we used a genetic algorithm to select the best features from a dataset with 365 probes and 62 samples. The 62 samples were randomly selected, with equal proportion of normal and tumor samples. The other 8 samples, 4 of each class, were kept separately, for consecutive validation of the results. The fitness function for the genetic algorithm was implemented upon a linear discriminant classifier (LDA). The genetic algorithm was set to minimize the error rate of the linear discriminant classifier, computed using 10-fold cross validation. Our aim was to determine which probes in our dataset are the most valuable for predicting the samples' class, rather than finding the smallest subset of features that can perfectly separate the normal and tumor arrays, on this specific dataset.
After we ran the Genetic Algorithm with 200 repetitions, over the training set with 62 samples and 365 probes, 45 features (Table 1 ) appeared with a frequency more than 18% in the selected features subsets. We applied the genetic algorithm implementation provided in the genalg R package. We used unsupervised, and then supervised machine learning methods to evaluate our results. We focused on the full dataset containing 54675 features and 70 samples, the dataset with 365 features and 70 samples, resulted following the filtering step, and the dataset with 45 features and 70 samples, outcome of the genetic algorithm. We wished to test if the smallest dataset, with just 45 features is efficient in discriminating the tumor from normal samples. We were also interested to compare the performance of well-known efficient classifiers on the two datasets.
We analyzed each dataset with the unsupervised methods, Divisive Analysis and Partitioning Around Medoids. The diana and pam implementations respectively, offered by the cluster R package, were employed for this task. For both methods we carried out the experiments using the Euclidean distance. We also applied Multidimensional Scaling (the sammon version implemented in the MASS R package) and PCA on the datasets. Some results of the unsupervised learning phase are presented in the Appendix A (Fig. 2-12) . The 8 samples excluded from the GA step were tested with a linear discriminant classifier trained on the same 62 samples set, that was presented to the GA, but with only 45 features.
We continued our analysis, illustrating the performance of two classifiers over the filtered dataset with 365 features and the one with 45 features, generated consequently to GA output analysis. For this purpose, we preferred the support vector machines (SVM) with linear kernel function, and the regularized discriminant (RDA) offered by the MLInterfaces R package. The performance of classifiers over each dataset was evaluated using 5-fold cross validation.
The results of both the unsupervised and supervised learning steps were encouraging, so it became interesting to check if our results could gain biological sense. We tested for significant pathways in our dataset using the procedure offered by the R package globaltest.
V. RESULTS
The performance of the linear discriminant classifier, trained with 62 samples, over the testing set with 8 samples is presented in Table 2 . Both classifiers performed better on the smaller dataset, with only 45 features. The results we got for the SVM with linear kernel and RDA are presented in the Table 3 . We notice that the supervised learning results were in agreement with the beliefs we had after analyzing the unsupervised learning results. The dataset with 45 features is more efficient in predicting the samples' class with linear kernel SVM or RDA classifiers. The test for significant pathways on the 45 features dataset showed that, even the dataset contains a very small number of genes, at lest five KEGG pathways are differentially expressed between the tumor and normal samples. The significant differentially expressed pathways in the 45 features dataset are presented in Table 4 . The pathways found significant in the dataset with 365 features are shown in Table 5 . 4 . We conclude that our approach is successful in selecting the most significant genes for predicting the samples' class.
We have reasons to believe that, in the next steps of the project we can establish a very specific subset of genes causally related with the evolution of pancreatic cancer. 
